依达拉奉联合血栓通对急性脑梗死的疗效及对神经功能缺损和日常生活能力的影响

目的:探讨依达拉奉联合血栓通治疗急性脑梗死(ACI)的临床疗效及对患者神经功能缺损和日常生活能力的影响。方法:将我院2011年1月-2013年1月收治的98例ACI患者按照入院先后顺序随机分为两组,每组各49例,其中对照组在对症治疗基础上加用依达拉奉,而观察组在对照组的基础上加用血栓通,对比两组临床疗效及患者神经功能缺损评分(NIHSS)、日常生活能力(ALD)评分及不良反应发生率。结果:观察组总有效率为91.92%,显著高于对照组的71.43%(P0.05);观察组治疗后NIHSS评分为(10.18±2.21)分,而ALD评分为(57.42±3.66)分,较对照组和治疗前均有显著改善(P0.05);两组不良反应发生率比较差异无统计学意义(P0.05)。结论:依达拉奉联合血栓通治疗ACI疗效显著,可明显改善患者神经功能缺损、提高日常生活能力,具有较好的临床应用价值。

The Clinical Effect of Xueshuantong Combined With Edaravone inTreatment of Acute Cerebral Infarction and Its Impact on NeurologicalDeficits and Activities of Daily Living

Objective:To investigate the effect of Xueshuantong combined with edaravone in treatment of acute cerebralinfarction (ACI) and the impact on neurologic impairment and activities of daily living.Methods:98 cases of ACI patients in our hospitalfrom January 2011 to January 2013 were randomly divided into two groups according to admission order, and each group had 49 cases,the control group was given edaravone on the basis of the symptomatic treatment while the observation group was given edaravone on thebasis of control group. The clinical efficacy, neurological deficit (NIHSS) score, activities of daily living (ALD) score changes andincidence rate of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was91.92% significantly higher than 71.43% of the control group (P<0.05); after treatment, the NIHSS score of the observation group was(10.18± 2.21) points, while ALD score was (57.42± 3.66) points, which significantly improved than before and the control group (P<0.05); The incidence rate of adverse reactions between two groups was no significant difference(P>0.05).Conclusion:Edaravone combinedwith Xueshuantong in treatment of ACI has good effect, and it can significantly improve patients'' neurological function and activities ofdaily living, which has better clinical value.